Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor for Patients With Relapsed AML
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 47
- 试验地点
- 1
- 主要终点
- Anti-leukemic Potential Efficacy, in Terms of Duration of Response (Arm II)
研究概览
简要总结
This phase I/II trial studies the side effects of laboratory-treated T cells and to see how well they work in treating patients with high-risk acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelogenous leukemia (CML) that has returned after a period of improvement (relapsed), previously treated with donor stem cell transplant. Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop cancer cells from growing. Placing a gene that has been created in the laboratory into a person's T cells may make the body build an immune response to kill cancer cells.
详细描述
PRIMARY OBJECTIVES:
I. Determine the safety and potential toxicities associated with treating patients with high risk or relapsed AML, MDS, and CML after allogeneic hematopoietic cell transplantation (HCT) by adoptive transfer of virus-specific cluster of differentiation (CD)8 T cells genetically-modified to express a high affinity Wilms tumor 1 (WT1)-specific T cell receptor (TCR).
II. Determine the anti-leukemic activity associated with treating patients with relapsed AML, MDS and CML after allogeneic HCT by adoptive transfer of virus-specific CD8 T cells genetically-modified to express a high affinity WT1-specific T cell receptor (TCR).
SECONDARY OBJECTIVES:
I. Determine the in vivo persistence of transferred T cells and ability to migrate to and accumulate in bone marrow.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must express HLA-A*0201
- •Patients who are currently undergoing or who previously underwent matched allogeneic HCT for:
- •AML: Prospective enrollment will now be limited to patients with relapsed disease (overt relapse or minimal residual disease) at any time post allogeneic HCT
- •MDS will no longer be a criterion for eligibility
- •CML will no longer be a criterion for eligibility
- •Patients must have an HLA-matched donor of hematopoietic stem cells (related or unrelated)
- •Patients must be able to provide blood and bone marrow samples and undergo the procedures required for this protocol
- •Patients must be >= 15 kg, as patients with lower weight would be incapable of providing high volume and frequent blood samples for monitoring and analysis
- •Patients must be able to give informed consent; parent or legal representative will be asked to consent for patients younger than 18 year old
- •DONOR: Patient and donor (related or unrelated) must be HLA-matched and express HLA-A*0201
- •DONOR: Donor must be Epstein-Barr virus (EBV) or cytomegalovirus (CMV) seropositive
- •DONOR: Donor must be age 18 or older
- •DONOR: In good general health
- •DONOR: Able to give informed consent
排除标准
- •Central nervous system (CNS) tumor refractory to intrathecal chemotherapy and/or cranio-spinal radiation
- •In patients whose leukemic cells are available for evaluation, the expression of WT1 in the patient's bone marrow will be determined; if WT1 expression in the patient's bone marrow is not highly expressed by polymerase chain reaction (PCR), the patient will be excluded from the study; patients with no evaluable leukemia will be eligible for enrollment based on the high frequency of positive leukemias (> 90%), and leukemia will be evaluated for WT1 expression if recurrence is detected
- •Human immunodeficiency virus (HIV) seropositive; testing for HIV should be within 6 months of enrollment
- •Medical or psychological conditions that would make the patient unsuitable candidate for cell therapy at the discretion of the principal investigator (PI)
- •Pregnancy or breast-feeding; women of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (B-hCG) pregnancy test result within 14 days before the first dose of WT1-specific T cell infusion; woman of non-childbearing potential will be defined as being postmenopausal greater than one year or who have had a bilateral tubal ligation or hysterectomy; all recipients of WT1-specific T cells will be counseled to use effective birth control during participation in this study and for 12 months after the last T cell infusion
- •DONOR: Less than 18 years old
- •DONOR: Active infectious hepatitis
- •DONOR: HIV or human T-lymphotropic virus (HTLV) seropositive
- •DONOR: Pregnancy or nursing
- •DONOR: Significant medical conditions (e.g. immunosuppressive therapy) that would make the donor an unsuitable T cell donor
- •DONOR: Unable to give informed consent
研究组 & 干预措施
Arm I (high-risk for relapse after HCT)
Patients with no evidence of leukemia or MDS post-HCT receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 14 and aldesleukin SC BID on days 14-28.
干预措施: Aldesleukin (Biological)
Arm I (high-risk for relapse after HCT)
Patients with no evidence of leukemia or MDS post-HCT receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 14 and aldesleukin SC BID on days 14-28.
干预措施: Laboratory Biomarker Analysis (Other)
Arm I (high-risk for relapse after HCT)
Patients with no evidence of leukemia or MDS post-HCT receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 14 and aldesleukin SC BID on days 14-28.
干预措施: WT1-Sensitized Allogeneic T-Lymphocytes (Biological)
Arm II (relapsed after HCT)
Patients with evidence of AML (minimal residual disease or overt relapse) post-HCT receive cyclophosphamide IV and fludarabine phosphate IV daily on days -4 to -2. Patients also receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 21 and aldesleukin SC BID on days 14-28.
干预措施: Aldesleukin (Biological)
Arm II (relapsed after HCT)
Patients with evidence of AML (minimal residual disease or overt relapse) post-HCT receive cyclophosphamide IV and fludarabine phosphate IV daily on days -4 to -2. Patients also receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 21 and aldesleukin SC BID on days 14-28.
干预措施: Cyclophosphamide (Drug)
Arm II (relapsed after HCT)
Patients with evidence of AML (minimal residual disease or overt relapse) post-HCT receive cyclophosphamide IV and fludarabine phosphate IV daily on days -4 to -2. Patients also receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 21 and aldesleukin SC BID on days 14-28.
干预措施: Fludarabine Phosphate (Drug)
Arm II (relapsed after HCT)
Patients with evidence of AML (minimal residual disease or overt relapse) post-HCT receive cyclophosphamide IV and fludarabine phosphate IV daily on days -4 to -2. Patients also receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 21 and aldesleukin SC BID on days 14-28.
干预措施: Laboratory Biomarker Analysis (Other)
Arm II (relapsed after HCT)
Patients with evidence of AML (minimal residual disease or overt relapse) post-HCT receive cyclophosphamide IV and fludarabine phosphate IV daily on days -4 to -2. Patients also receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 21 and aldesleukin SC BID on days 14-28.
干预措施: WT1-Sensitized Allogeneic T-Lymphocytes (Biological)
结局指标
主要结局
Anti-leukemic Potential Efficacy, in Terms of Duration of Response (Arm II)
时间窗: Up to 1 year
Response is assessed throughout the 1 year post treatment timeframe. Morphologic criteria for response: Complete Response (CR) = Bone Marrow blasts \<5%; no blasts with Auer rods; no extramedullary disease. Transfusion independent. Platelets ≥ 100,000/μl Absolute neutrophil count \>1000/μl (CRi: incomplete hematologic recovery CRp: incomplete platelet recovery) Partial Response (PR) = Decrease of at least 50% in the percentage of blasts to 5-25% in the bone marrow and the normalization of blood counts as for CR. (PRi and PRp if incomplete hematologic or platelet recovery) Stable Disease (SD) = Failure to achieve at least PR, but no evidence of progression for \>4 weeks.
Efficacy, in Terms of Relapse Rate (Arm I)
时间窗: At 1 year post-transplant
Count of Participants Who Experienced Chronic Graft Versus Host Disease (GVHD) (Arm I)
时间窗: Up to 1 year
Count of Participants Who Experienced Grade III-IV Acute Graft Versus Host Disease (GVHD) (Arm II)
时间窗: Up to 1 year following infusion per patient
Count of Participants Who Experienced Grade III-IV Acute Graft-versus-host Disease (GVHD) (Arm I)
时间窗: Up to 1 year
Count of Participants Who Experienced Chronic Graft Versus Host Disease (GVHD) (Arm II)
时间窗: Up to 1 year
Treatment-related Toxicity Rate (Arm I)
时间窗: Up to 30 days after last study intervention per patient
Outcome will be reported as a count of participants that experienced adverse events. Toxicity will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 4.0
Treatment-related Toxicity Rate (Arm II)
时间窗: Up to 30 days after last study intervention per patient
Outcome will be reported as a count of participants that experienced adverse events. Toxicity will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 4.0
次要结局
- Incidence of Relapse After T Cell Therapy (Arm II)(Up to 1 year)
- Maintenance of T Cell Receptor (TCR) Expression of Transduced T Cells (Arm I) i.e. Persistence(Up to 28 days post intervention per patient)
- Disease-free Survival After T Cell Therapy(Up to 1 year)
- Maintenance of Function of Transduced T Cells (Arm I)(Up to 28 days post intervention per patient)
- Time to Progression After T Cell Therapy (Arm I)(Up to 1 year)
研究者
Aude Chapuis
Associate Professor, Program in Immunology
Fred Hutchinson Cancer Center